Astrazeneca Plc (AZN) |
|
52.6 -0.97 (-1.81%)
|
11-27 01:34 |
|
Open: |
52.34 |
Pre. Close: |
53.57 |
|
High:
|
53.09 |
Low:
|
52.3 |
|
Volume:
|
11,536,903 |
Market Cap:
|
136,777M |
|
|
|
|
AstraZeneca PLC discovers, develops, and commercializes prescription medicines in the areas of oncology, cardiovascular, renal and metabolism, respiratory, autoimmunity, infection, neuroscience, and gastroenterology worldwide. Its marketed products include Arimidex, Casodex/Cosudex, Calquence, Faslodex, Imfinzi, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor, Plendil, Seloken/Toprol-XL, Tenormin, and Zestril for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR/Komboglyze, Onglyza, Qtern, Symlin, Xigduo/Xigduo XR for metabolic diseases. The company's marketed products also comprise Accolate, Bevespi Aerosphere, Bricanyl Respules, Bricanyl Turbuhaler, Daliresp/Daxas, Duaklir Genuair, Tudorza/Eklira, Fasenra, Oxis Turbuhaler, Pulmicort Turbuhaler/Pulmicort Flexhaler, Pulmicort Respules, Symbicort pMDI, and Symbicort Turbuhaler for respiratory diseases; Fluenz Tetra/FluMist Quadrivalen and Synagis for infection diseases; Movantik/Moventig, Seroquel IR/Seroquel XR, and Vimovo for neuroscience diseases; and Losec/Prilosec and Nexium for gastrointestinal diseases. The company serves primary care and specialty care physicians through distributors and local representative offices. It has a collaboration agreement with Arcus Biosciences, Inc. to evaluate domvanalimab (AB154), an investigational anti-TIGIT antibody in combination with Imfinzi (durvalumab); and Fusion Pharmaceuticals Inc. to develop and commercialize next-generation alpha-emitting radiopharmaceuticals and combination therapies for the treatment of cancer. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was founded in 1992 and is headquartered in Cambridge, the United Kingdom. |
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
53.203 - 53.523 |
53.523 - 53.761 |
|
Low:
|
51.531 - 51.958 |
51.958 - 52.275 |
|
Close:
|
52.041 - 52.67 |
52.67 - 53.137 |
|
Technical analysis |
as of: 2020-11-25 4:35:54 PM |
|
Overall:
|
 |
| Stoxline posted a SELL today, same as yesterday. Downward movement continues. |
| Target: |
Six months: 64.14 One year: 67.84 |
| Support: |
Support1: 49.79 Support2: 41.43 |
| Resistance: |
Resistance1: 54.91 Resistance2: 58.08 |
| Pivot: |
55.27  |
| Moving Average: |
MA(5): 54.04 MA(20): 54.38 
MA(100): 54.96 MA(250): 51.64 |
| MACD: |
MACD(12,26): 0.10 Signal(9): 0.37 |
| Stochastic oscillator: |
%K(14,3): 20.15 %D(3): 38.55 |
| RSI: |
RSI(14): 43.05 |
| 52-week: |
High: 64.94 Low: 36.15 Change(%): 8.5 |
| Average Vol(K): |
3-Month: 492050 10-Days: 666679 |
|
Price, moving averages and Bollinger Bands |
|
Price and moving averages has closed below its Short term moving average. Short term moving average is currently above mid-term; AND above long term moving averages. From the relationship between price and moving averages; we can see that: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.AZN has closed above bottom band by 4.7%. Bollinger Bands are 21.3% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices. |
|
|
Headline News |
Thu, 26 Nov 2020
AstraZeneca faces criticism over COVID-19 vaccine trials results - Proactive Investors UK
Thu, 26 Nov 2020
AstraZeneca Faces More Vaccine Questions After Manufacturing Error - Bloomberg
Mon, 23 Nov 2020
Astra Shot That Works Better in Small Doses Raises Questions - Bloomberg
Mon, 23 Nov 2020
The Chart for AstraZeneca PLC (AZN) Is Flashing Mixed Signals - The News Heater
Mon, 23 Nov 2020
AstraZeneca (AZN)-Oxford Covid-19 Vaccine Prevents Average of 70% of Covid Cases - Bloomberg
Thu, 19 Nov 2020
AstraZeneca Stock Flat Despite Encouraging Vaccine Update - Schaeffers Research
|
Financial Analysis |
| Growth |
 |
| Growth measures the growth of both a company's revenue and net income. it tells investors how fast a company is growing. |
| Profitability |
 |
| Profitability measures a company’s ability to generate earnings as compared to its expenses and other relevant costs. |
| Solvency |
|
| Solvency measures a company's ability to meet its long-term debts. Acceptable solvency ratios will vary from industry to industry. |
| Efficiency |
|
| Efficiency measures the strength of a company's return on invested capital. It can identify business that are better managed or not. |
| Price to Book Value: |
Outperform |
Discounted cash flow: |
Outperform |
| Return on Assets: |
Neutral |
Price to Earnings: |
Outperform |
| Return on Equity: |
Neutral |
Debt to Equity: |
Outperform |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Drug Manufacturers General |
| Shares Out. (M) |
2,620 |
| Shares Float (M) |
2,620 |
|
% Held by Insiders
|
|
|
% Held by Institutions
|
17.31 |
|
Shares Short (K)
|
6,050 |
|
Shares Short P. Month (K)
|
5,100 |
Stock Financials |
|
EPS
|
0.950 |
|
EPS Est This Year
|
1.910 |
|
EPS Est Next Year
|
1.700 |
|
Book Value (p.s.)
|
4.650 |
|
Profit Margin
|
9.65 |
|
Operating Margin
|
19.86 |
|
Return on Assets (ttm)
|
5.2 |
|
Return on Equity (ttm)
|
17.7 |
|
Qtrly Rev. Growth
|
2.7 |
|
Gross Profit (p.s.)
|
7.458 |
|
Sales Per Share
|
9.874 |
|
EBITDA (p.s.)
|
2.939 |
|
Qtrly Earnings Growth
|
116.70 |
|
Operating Cash Flow (M)
|
4,380 |
|
Levered Free Cash Flow (M)
|
4,980 |
Stock Valuations |
|
PE Ratio
|
55.37 |
|
PEG Ratio
|
1.33 |
|
Price to Book value
|
11.31 |
|
Price to Sales
|
5.33 |
|
Price to Cash Flow
|
31.46 |
Stock Dividends |
|
Dividend
|
2.800 |
|
Forward Dividend
|
1.400 |
|
Dividend Yield
|
0.05 |
|
Dividend Pay Date
|
2020-09-13 |
|
Ex-Dividend Date
|
2020-08-12 |
|
7 Binary Options
|
|
Your Ad Here
|
|
